PAVmed Inc. (NASDAQ:PAVM) Shares Acquired by First Manhattan CO. LLC.

First Manhattan CO. LLC. lifted its stake in shares of PAVmed Inc. (NASDAQ:PAVM) by 16.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 700,000 shares of the company’s stock after purchasing an additional 100,000 shares during the period. First Manhattan CO. LLC. owned 6.32% of PAVmed worth $439,000 as of its most recent SEC filing.

Wall Street Analyst Weigh In

Separately, Ascendiant Capital Markets boosted their target price on PAVmed from $19.00 to $19.50 and gave the stock a “buy” rating in a report on Monday, April 21st.

PAVmed Price Performance

Shares of PAVmed stock opened at $0.67 on Monday. The stock has a market cap of $11.41 million, a P/E ratio of -0.15 and a beta of 1.11. The stock’s 50 day simple moving average is $0.71 and its 200-day simple moving average is $0.77. PAVmed Inc. has a 1-year low of $0.55 and a 1-year high of $2.35.

About PAVmed

PAVmed Inc focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.